1. Home
  2. NEGG vs LPTX Comparison

NEGG vs LPTX Comparison

Compare NEGG & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NEGG
  • LPTX
  • Stock Information
  • Founded
  • NEGG 2001
  • LPTX 2011
  • Country
  • NEGG United States
  • LPTX United States
  • Employees
  • NEGG N/A
  • LPTX N/A
  • Industry
  • NEGG Other Specialty Stores
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NEGG Consumer Discretionary
  • LPTX Health Care
  • Exchange
  • NEGG Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • NEGG 116.0M
  • LPTX 119.6M
  • IPO Year
  • NEGG 2010
  • LPTX N/A
  • Fundamental
  • Price
  • NEGG $0.25
  • LPTX $0.31
  • Analyst Decision
  • NEGG
  • LPTX Buy
  • Analyst Count
  • NEGG 0
  • LPTX 2
  • Target Price
  • NEGG N/A
  • LPTX $8.00
  • AVG Volume (30 Days)
  • NEGG 703.9K
  • LPTX 5.8M
  • Earning Date
  • NEGG 04-23-2025
  • LPTX 03-26-2025
  • Dividend Yield
  • NEGG N/A
  • LPTX N/A
  • EPS Growth
  • NEGG N/A
  • LPTX N/A
  • EPS
  • NEGG N/A
  • LPTX N/A
  • Revenue
  • NEGG $1,391,833,000.00
  • LPTX N/A
  • Revenue This Year
  • NEGG $6.01
  • LPTX N/A
  • Revenue Next Year
  • NEGG N/A
  • LPTX N/A
  • P/E Ratio
  • NEGG N/A
  • LPTX N/A
  • Revenue Growth
  • NEGG N/A
  • LPTX N/A
  • 52 Week Low
  • NEGG $0.24
  • LPTX $0.28
  • 52 Week High
  • NEGG $1.32
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • NEGG 27.51
  • LPTX 25.59
  • Support Level
  • NEGG $0.25
  • LPTX $0.41
  • Resistance Level
  • NEGG $0.32
  • LPTX $0.65
  • Average True Range (ATR)
  • NEGG 0.03
  • LPTX 0.05
  • MACD
  • NEGG -0.00
  • LPTX 0.03
  • Stochastic Oscillator
  • NEGG 8.12
  • LPTX 6.78

About NEGG Newegg Commerce Inc.

Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Share on Social Networks: